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Asthma aects approximately 2–5 % of the adult popula-
tion in most Western countries, whereas the prevalence in
children is notably higher (2–20%) (1). The cardinal
symptoms of asthma—wheezing, breathlessness and chest
tightness—are all caused by airflow obstruction due to a
combination of inflammatory oedema of the airway wall
and constriction of airway musculature. Although anti-
inflammatory therapy with glucocorticoids is recommended
in all but the mildest cases of asthma, bronchodilators are
still drugs of first-line therapy in order to reverse and/or
inhibit bronchoconstriction, thereby improving (or normal-
izing) respiratory function and producing symptomatic
relief (2). b2-adrenoceptor agonists (e.g. terbutaline and
salbutamol) and methylxanthines [mainly theophylline (1,3-
dimethylxanthine)], either alone or in combination, have
traditionally been used as bronchodilators. Other drugs
producing airway smooth muscle relaxation or interfering
with mediators of airway smooth muscle contraction could
in theory be used as well. This includes potassium channel
openers, calcium channel blockers, isoenzyme-selective
phosphodiesterase (PDE) inhibitors, nitric oxide (NO)
donors, neuropeptides such as vasoactive intestinal peptide
(VIP) or atrial natriuretic peptide (ANP), anticholinergics,
leukotriene- and tachykinin-receptor antagonists and many
others (3,4). Many questions regarding the mechanisms
involved in airway smooth muscle relaxation produced by
these drugs have not yet been answered.
The present review consists of two parts. In this first part
airway smooth muscle electrophysiology, excitation–con-
traction coupling and autonomic innervation of the airways
will be discussed. Moreover, a brief discussion of possible
mediators of (asthmatic) airway smooth muscle contraction
will be presented. The second part of the review will focus
on the pharmacology of dierent airway smooth muscleReceived 13 August 1999 and accepted in revised from 28
November 1999.
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Setting of membrane potential
The resting membrane potential of airway smooth muscle
cells ranges from 745 to 760 mV (6). In most species, for
example cows and dogs, the membrane potential is stable,
but in humans and guinea-pigs the membrane potential
oscillates in a characteristic manner called slow waves.
These waves were initially observed in guinea-pig tracheal
smooth muscle (7) and later reported to exist in both
tracheal (8) and bronchial (9) smooth muscles from
humans. Mean amplitude and frequency of slow waves
in guinea-pig tracheal smooth muscle are approximately
12mV and 50 wavesmin71 with the average membrane
potential close to750mV, whereas these values are a little
smaller in human preparations (approximately 8mV, 20
wavesmin71 and average membrane potential 745mV)
(6). In addition to spontaneous electrical activity, both
guinea-pig and human airways exhibit prominent sponta-
neous tone when studied in vitro. In guinea-pig airways this
tone is due to continuous synthesis and release of
prostaglandins (10,11), mainly mediated by the second
isoform of cyclooxygenase (COX-2) (12). The spontaneous
tone in human preparations is most likely caused by
histamine and leukotrienes, (9,13) with some involvement
of cyclooxygenase products and airway epithelium (14).
Since guinea-pig and human airways are the only airway
preparations simultaneously showing spontaneous electri-
cal and mechanical activity, it has been suggested that these
two phenomena both could be caused by the special
characteristic of the endogenous production of arachidonic
acid products (6). However, studies in guinea-pig trachea
(15,16) and human bronchi (9) have failed to support this
hypothesis and the exact mechanisms underlying sponta-
neous electrical slow wave activity have not yet been fully
established.
Although guinea-pig and human airway smooth muscles
have slow wave activity these waves seldom convert into
spiking action potentials and airway smooth muscle
membranes generally display strong outward rectification
(6). Outward rectification means that any attempt to# 2000 HARCOURT PUBLISHERS LTD
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of potassium channels, increasing the eux of K+, tending
to cause hyperpolarization of the membrane and thereby
counteracting the depolarization. At present at least 14
dierent K+ channels have been identified (17), but only a
few of them have been shown to exist in the airway smooth
muscle membranes. Two of these K+ channels, the large
conductance Ca2+-activated K+ channel (BKCa) and the
delayed rectifier K+ channel (KV), have been identified as
the channels responsible for the strong outward rectifying
behaviour of airway smooth muscles (18–21). BKCa is a
calcium- and voltage-sensitive K+ channel meaning that
the open-state probability of this channel increases both in
response to elevation of the intracellular calcium concen-
tration and membrane depolarization (19,20). In addition,
the activity of BKCa also seems to be regulated by
G-proteins and intracellular second messengers during
drug-induced smooth muscle contraction as well as relaxa-
tion. KV is a voltage-sensitive K
+ channel only increasing
open-state probability in response to relative large (4 20
mV) membrane depolarization (19,20). In order to study
these channels selective inhibitors are needed. Charybdo-
toxin (ChTX, from the scorpion Leiurus quinquestriatus)
and especially iberiotoxin (IbTX, from the scorpion Buthus
tamulus) are highly selective inhibitors of BKCa (22).
Tetraethyl ammonium (TEA) in the concentration range
0.1–10 mM is also an eective inhibitor of BKCa, but
concentrations higher than 1 mM tend to aects other K+
channels as well (19,20). 4-aminopyridin (1–5 mM) seems
not to inhibit K+ channels other than KV and is therefore
considered to be the most useful pharmacological tool for
the investigation of this channel (19,20).
In addition to BKCa and KV, two other K
+ channels
have attracted interest in airway physiology and pharma-
cology. One of these channels is the small conductance
Ca2+-activated K+ channel (SKCa) which is selectively
blocked by the toxin apamin (from the honeybee Apis
mellifera) (22). SKCa is mainly a Ca
2+-sensitive channel
with very little voltage-dependence and until recently there
was very little evidence for the existence of these channels in
either human or animal airway smooth muscles (20).
However, apamin has been reported to antagonize antigen
induced contractions of guinea-pig isolated airways (23)
and inhibit the relaxant response to urodilatin in isolated
bovine bronchi (24), thereby providing indirect evidence for
the existence of SKCa in these airways. Evidence for the
existence of SKCa in human airway smooth muscles is still
lacking. The other K+ channel of interest in airway
pharmacology and physiology is the adenosine tripho-
sphate (ATP)-sensitive K+ channel (KATP). This channel
was initially discovered in the heart (25) and later shown to
mediate the glucose-stimulated insulin secretion from
pancreatic b-cells (26,27). Anti-diabetic sulphonylureas
such as tolbutamide, glibenclamide and glipizide promote
insulin secretion by selective blockade of KATP (28,29).
Besides their existence in pancreatic b-cells, patch-clamp
studies have identified ATP-sensitive K+ channels in
vascular (30) and airway (31) smooth muscle which are
blocked by glibenclamide and activated by K+ channel
openers, such as cromakalim (BRL 34915) or its activeenantiomer levcromakalim (BRL 38227). Further evidence
for the existence of KATP in airway smooth muscle comes
from studies showing that cromakalim produces airway
smooth muscle relaxation accompanied by hyperpolariza-
tion (32,33), and that these events are blocked by
glibenclamide (33,34).
The main factors determining the resting membrane
potential of smooth muscle are the concentration gradient
and conductance of potassium ions across the membrane.
Although BKCa and KV seems to be involved in the
generation of slow wave activity in airway smooth muscle
neither of these channels nor KATP seems to be important in
the setting of the resting membrane potential (35,36).
Therefore, other K+ channels, such as the inward rectifier
K+ channel (KIR) (37), may be responsible for the
determination of the resting membrane potential of airway
smooth muscles, but further studies are needed.
Excitation–contraction coupling
Whether smooth muscle contraction is initiated by depo-
larization (electro-mechanical coupling) or by stimulation
with a contractile agonist (pharmaco-mechanical coupling)
it is intimately linked to a rise in the intracellular
concentration of free Ca2+ ions ([Ca2+]i). Under normal
physiological conditions the extracellular Ca2+-concentra-
tion is in the range of 1–2 mM whereas [Ca2+]i in resting
(relaxed) airway smooth muscle is approximately 150 nM
(38). This large dierence in calcium concentration
(approximately 104) provides a concentration-gradient
down which Ca2+ will tend to flow. Under resting
conditions only few Ca2+ ions enter the cell and [Ca2+]i
is maintained relatively constant due to dierent homoeo-
static mechanisms. These includes (1) a plasmamembrane
Na+-Ca2+ exchanger driven by the Na+ gradient (main-
tained by the Na+-K+-ATPase) into the cells, (2) a Mg2+-
dependent plasmamembrane Ca+-H+-ATPase and (3) a
sarcoplasmic reticulum Ca2+-ATPase (39). Following
excitation of airway smooth muscle [Ca2+]i rises rapidly
to a peak concentration of about 800 nM which, during
continuous stimulation, is succeeded (after 45–60 sec) by a
sustained elevation of [Ca2+]i near 300 nM (38). The initial
rise in [Ca2+]i causes the formation of a Ca
2+-calmodulin
complex which activates the enzyme myosin light chain
kinase (MLCK). MLCK is responsible for the phosphor-
ylation of the 20 kDa light chains of myosin (MLC20),
thereby activating the myosin ATPase and allowing the
formation of cross-bridges between actin and myosin. The
rapid formation, breaking and reformation of cross-bridges
(cross-bridge cycling) is responsible for the initiation of
contraction. As [Ca2+]i declines MLCK becomes inactive
and MLC20 is dephosphorylated but despite of this the level
of contraction is maintained as long as [Ca2+]i is above
basal levels. The detailed events underlying this main-
tenance of force are currently not known but several
mechanisms have been proposed. These include the
formation of altered and/or slowly cycling actin–myosin
cross-bridges (latch-bridges), inhibition of the phosphatase
330 S. THIRSTRUPthat dephosphorylates the MLC20 and altered Ca
2+-
sensitivity of the contractile filaments (39,40) .
Pharmaco-mechanical coupling is initiated by the bind-
ing of a contractile agonist to its receptor, thereby
activating the enzyme phospholipase C (PLC) through
membrane-bound guanine nucleotide regulatory proteins
(G-proteins). PLC cleaves the membrane phospholipid
phosphatidyl inositol-4,5-biphosphate into inositol-1,4,5-
triphosphate (IP3) and diacylglycerol (DAG). IP3 induces
the release of sarcoplasmic Ca2+ causing the rapid rise in
[Ca2+]i and initiation of contraction, whereas DAG,
through its activation of protein kinase C, takes part in
force maintenance (39,41). Influx of extracellular Ca2+
through dihydropyridine-sensitive voltage-operated Ca2+
channels (VOC) (42) seems only to make a small contribu-
tion to the rise in [Ca2+]i during pharmaco-mechanical
coupling in airway smooth muscle (43–47), but may be
involved in the refilling of intracellular Ca2+ stores (48). On
the other hand, Ca2+ influx through receptor-operated
Ca2+ channels (ROC) seems to be responsible for the
sustained elevation of [Ca2+]i during agonist-induced
contractions (38). The rise in [Ca2+]i would tend to activate
BKCa, thereby counteracting agonist-induced contraction
by hyperpolarization, but G-protein linked inhibition of
BKCa most likely osets this mechanism (49).FIG. 1 Main mechanisms involved in excitation-contraction coup
either by 1. membrane depolarisation and opening of voltage-o
protein (Gq) coupled receptors with a contractile agonist. PLC
biphosphate; IP3: inositol-1,4,5-triphosphate; SR: sarcoplasmic
MLCK: myosin light chain kinase; BKCa: large conductance CDuring electro-mechanical coupling cellular depolariza-
tion (e.g. induced by elevation of extracellular K+
concentration) opens dihydropyridine-sensitive VOC pro-
moting Ca2+ influx. This influx, eventually supported by
Ca2+-mediated sarcoplasmic Ca2+-release (39), causes the
rise in [Ca2+]i necessary for contraction.
The cellular mechanisms underlying excitation–contrac-
tion coupling in airway smooth muscle are schematically
illustrated in Fig. 1.
Autonomic innervation
The neural innervation of airway smooth muscle is
complex. In addition to sympathetic (adrenergic) and
parasympathetic (cholinergic) innervation accumulating
evidence supports the existence of non-adrenergic non-
cholinergic (NANC) innervation of the respiratory tract.
This third division of the autonomic nervous system is
made up of two parts: 1. an inhibitory component
(i-NANC) mediating relaxation and 2. an excitatory
component (e-NANC) mediating contraction of airway
smooth muscle. Moreover, neural interactions at pre- and
post-junctional sites between the dierent functional parts
of the autonomic nervous system and neurotransmitterling in airway smooth muscle. Contractions can be induced
perated Ca2+ channels (VOC) or by 2. stimulation of G-
: phospholipase C; Pt-IP2: phosphatidyl inositol-4,5-
reticulum; DAG: diacylglycerol; PKC: protein kinase C;
a2+-activated K+ channel; : stimulation; 	: inhibition.
CONTROL OF AIRWAY SMOOTH MUSCLE TONE 331co-transmission further contribute to the complexity.
Discrepancies regarding the relative contribution of the
dierent parts of the autonomic nervous system as well as
species and anatomically variations exist. These items will
be briefly reviewed in the following sections.
CHOLINERGIC INNERVATION
Guinea-pig and human airways receive a prominent
cholinergic innervation. Preganglionic fibres travel down
the vagus nerve to parasympathetic ganglia located in the
airway wall outside the smooth muscle and cartilage
(50,51). Using histochemical detection of acetylcholinester-
ase postganglionic cholinergic nerve fibres have been found
in close contact with human bronchial smooth muscles and
glands (51). These fibres extend from the lobar bronchi to
the terminal bronchioles, but the number of fibres in the
smooth muscle layer are highest in the lobar and first
segmental bronchi (51). This is in accordance with the
observation in other species that cholinergic innervation is
greatest in large central airways and diminishes peripherally
(50). Resting bronchial tone in both animals and humans is
dependent on a tonic parasympathetic activity (52) and
many indirect contractile mediators cause reflex broncho-
constriction through liberation of acetylcholine from
parasympathetic nerves (cf. Table 1). Presynaptic inhibition
of acetylcholine liberation is mediated by muscarinic M2
autoreceptors in both humans and guinea-pigs and
presynaptic a2- or b2-adrenoceptors in guinea-pig or human
airways respectively (52).
ADRENERGIC INNERVATION
Histochemical studies of human airways have demon-
strated catecholamine-containing nerve fibres in close
contact with bronchial vessels and glands whereas fibres
in the smooth muscle layer were almost absent (51).
Adrenergic fibres were detected from the level of the lobar
bronchi to the terminal bronchioles and were greatly
outnumbered by acetylcholine-containing nerve fibres
(51). Despite the presence of adrenergic fibres electrical
field stimulation of human isolated bronchi and bronchioles
elicited relaxant responses which were unresistant to high
concentrations of propranolol (53), indicating that the
adrenergic innervation of human airways is of limited
functional importance with respect to bronchodilation.
However, adrenergic fibres could modulate cholinergic
neurotransmission (as described above). The potent
bronchodilator activity of b2-adrenoceptor agonists is in
marked contrast to the lack of adrenergic innervation in
human airways and it is generally believed that lung b2-
adrenoceptors are the target for circulating catecholamines
rather that neuronal noradrenaline (52).
In contrast to human airways, adrenergic fibres innervat-
ing the smooth muscle layer of guinea-pig airways have
been demonstrated. The density of these fibres was highest
in the trachea, especially at the proximal (laryngeal) end,
and they were almost absent in more peripheral airways
(54). Electrical field stimulation of isolated guinea-pigtrachea reveals a relaxant response that is partially blocked
by propranolol and further confirms that the adrenergic
innervation predominates in anatomically proximal parts of
this preparation (55,56).
NON-ADRENERGIC NON-CHOLINERGIC
INNERVATION
Electrical field stimulation of guinea-pig (56) and human
(53) airway smooth muscle preparations has revealed an
inhibitory non-adrenergic non-cholinergic (i-NANC) in-
nervation. In guinea-pig airways both VIP and NO have
been identified as the transmitters mediating NANC
relaxations (57,58). In these airways the number of nerve
fibres containing the enzyme nitric oxide synthase increases
from proximal trachea to the principal bronchi, and from
there decreases to complete absence in the bronchioles (59).
In addition to the direct bronchodilator action of i-NANC,
modulation of cholinergic and e-NANC neurotransmission
has been established in guinea-pig airways (60,61). In
human airways i-NANC innervation seems to be the only
functional bronchodilator innervation (53) and a possible
defect in i-NANC has been postulated as part of asthma
pathophysiology (52). Although VIP-containing nerve
fibres have been found in layers of bronchial smooth
muscle from the level of the lobar bronchi to the small
bronchioles (51) it has only been possible to establish a
functional role for NO as i-NANC neurotransmitter in
human airways (62,63). In addition, VIP and NO could
possibly modulate cholinergic and e-NANC neurotransmis-
sion as in guinea-pigs but such eects have only been
established for NO on cholinergic neurotransmission (64).
The physiological and pathophysiological significance of
VIP-containing nerve fibres in human airways has not yet
been established.
Contractile responses that are resistant to cholinergic
blockade with atropine can be evoked in guinea-pig trachea
and main bronchi (65,66). These responses are most
prominent in distal compared to proximal trachea and
can be abolished by pretreatment with capsaicin (65).
Capsaicin selectively depletes sensory neurons for their
content of tachykinins (67), and substance P and neuroki-
nin A are the most likely candidates as neurotransmitters of
e-NANC neurotransmission in guinea-pig airways (68). In
isolated human airways contractile responses resistant to
atropine are rarely seen (52,68). It has been suggested that
e-NANC neurotransmission only becomes manifest in
diseases like asthma (52), mediating neurogenic inflamma-
tion and airway smooth muscle contraction as a conse-
quence of tachykinin release through an axon-reflex (69).
However, evidence in favour of this hypothesis in humans is
sparse. Inhalation of capsaicin (which depletes sensory
nerves for their content of neuropeptides) only causes
cough and transient bronchoconstriction and inhibition of
neuropeptide degradation neither worsens existing asthma
nor exaggerates symptoms following bronchial provocation
(70)
The NANC innervation of airway smooth muscle seems
to be involved in the regulation of diurnal variation in
TABLE 1. Cellular origin and contractile mechanism for mediators of airway smooth muscle contraction. The contractile mechanisms underlying the action of each mediator
have been classified as either direct or indirect. Receptors involved in the action of direct acting mediators are found in the table as well as substances involved in the action
of indirect acting mediators. For each contractile mediator the current evidence (references in parentheses) for its involvement in asthmatic airway smooth muscle
contraction has been evaluated: +++: involved (major role); ++: involved (minor role); +: possibly involved; 0: not involved; ?: not settled. Ach.: acetylcholine; AMP:
adenosine-monophosphate; AR: axon-reflex; His.: histamine; LTs: leukotrienes; NP: neuropeptides; PGs: prostaglandins; TXA2: thromboxane A2.
Contractile mediator Cellular origin Contractile mechanism Role as contractile
Direct Indirect mediator in asthma
Acetylcholine Parasympathetic nerves M3 +++ (52)
Adenosine Extracellular dephosphorylation of AMP from mast cells
and leukocytes
His. liberation 0/+ (73–77)
Ach. + NP via AR
PGs + LTs involved
Bradykinin Cleavage of kininogens by plasma- or tissue-kallikrein Ach. + NP via AR 0/+ (73,78,79)
Endothelins Epithelial cells, vascular endothelium, inflammatory cells ETB PGs from inflammatory cells +/? (80–82)
(ET-1, -2, -3) Ach. + NP via AR
Histamine Mast cells H1 Ach. via AR 0 (73,83,84)
Leukotrienes Mast cells, macrophages, eosinophils, neutrophils, epithelial cells, platelets
LTB4 TXA2 synthesis ? 85
LTC4 CysLT1 +++
LTD4 CysLT1 +++ (83,85–88)
LTE4 CysLT1
Neuropeptides Terminal sensory nerve fibres
Substance P NK1 ++ (60,70,85,89–93)
Neurokinin A NK2 ++
CGRP Unknown ? (70,98)
Platelet-activating
factor
Platelets, macrophages, eosinophils, neutrophils, (mast cells) PAF LTs from eosinophils 0/+ (73,94–98)
TXA2 from platelets
Ach. + NP via AR
Prostaglandins Mast cells, macrophages, neutrophils, epithelial cells Ach. via AR +/? (73,83,99)
PGD2 (PGE2) DP
PGF2a FP
Serotonin Nerve terminals, neuroendocrine cells 5-HT2 subtypes 0 (73,83)
Thromboxane Macrophages, platelets TP Ach. via AR +/? (73,83,99)
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CONTROL OF AIRWAY SMOOTH MUSCLE TONE 333airway tone (71) and to be responsible for the maintenance
of basal tone (72). Drug-induced modulation of either i- or
e-NANC is therefore of considerable interest. Many drugs
have been shown to modulate e-NANC neurotransmission
and with regard to anti-asthmatic drugs most of them
possess an inhibitory action against contractions induced
by electrical field stimulation (68). In contrast to this, only a
few studies have investigated the possible modulator eects
of anti-asthmatic drugs against i-NANC (55,68).
Mediators of contraction
Many dierent substances have been identified as possible
mediators of asthmatic airway smooth muscle contraction.
Most of these substances are produced by inflammatory
cells and possess a wide range of biological actions in
addition to their action as potential contractile mediators.
These actions include increased vascular permeability and
exudation of plasma proteins, resulting in oedema of the
airway wall, increased mucus production obstructing the
airway lumen and epithelial destruction exposing and
stimulating underlying sensory C-fibres resulting in release
of contractile neurotransmitters via an axon-reflex. Con-
tractile mediators are able to produce airway smooth
muscle contraction either through direct stimulation of G-
protein coupled receptors located in the smooth muscle cell-
membrane (pharmaco-mechanical coupling) or through
indirect pathways involving release and/or synthesis of
other direct acting mediators. Table 1 summarizes the
cellular origin, as well as the contractile mechanism
(classified as either direct or indirect), for a wide range of
contractile mediators possibly involved in the pathophy-
siology of asthma. Receptors involved in mediating airway
smooth muscle contraction are stated for direct acting
mediators and substances involved in the action of indirect
acting mediators are also found. Moreover, for each
mediator its potential involvement in asthmatic airway
smooth muscle contraction has been evaluated. The result
of this evaluation is based on the degree of fulfilment of the
following four criteria: 1. the substance must be produced
by cells found in asthmatic airways, 2. exogenous applica-
tion of the substance to healthy airways must induce
bronchoconstriction as well as symptoms of asthma, 3.
concentrations of the substance and/or its metabolites
found in blood, urine or broncho-alveolar lavage fluid
(BAL-fluid) must be higher in asthmatic than non-
asthmatics and 4. the pathophysiological changes (includ-
ing bronchocontriction) found in asthmatic airways must
be reversed by selective antagonists or inhibitors of
mediator biosynthesis/release.
Only acetylcholine and the leukotrienes C4, D4 and E4
have fully met these criteria and they are the mediators
currently believed to be of central importance in asthmatic
airway smooth muscle contraction. Moreover, acetylcho-
line released by an axon-reflex from parasympathetic nerve
endings seems to be involved in the action of many indirect
acting airway smooth muscle contractors (cf. Table 1). The
neuropeptides substance P and neurokinin A, which also
can be released from nerve endings (NANC nerves) via anaxon-reflex, seems to be important in mediating cough and
symptoms of chest tightness whereas their contribution to
airway inflammation and asthmatic bronchoconstriction
are of limited importance. Further studies including studies
with potent and selective receptor-antagonists and/or
inhibitors of biosynthesis must be awaited to fully settle
the exact role of many other subsantces such as endothelins
(ET-1, -2 and -3), prostaglandins and thromboxane as
mediators of asthmatic airway smooth muscle contraction.
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